The company received a complete response letter from the Food and Drug Administration regarding the biosimilar, meaning it won’t be approving its application in its submitted form.
The deal adds to Lannett’s portfolio various oral solutions and semi-solid products that had more than $175 million in sales for the 12 months ended in March, according to IQVIA data.